1. Introduction and Virological Background
Human papillomavirus (HPV) comprises more than 200 distinct genotypes, broadly classified by oncogenic potential into high-risk (HR) types—predominantly HPV16 and HPV18, which together drive the majority of HPV-attributable malignancies—and low-risk (LR) types such as HPV6 and HPV11, which are responsible for genital warts and recurrent respiratory papillomatosis (RRP). HPV is the most common sexually transmitted infection worldwide, with transmission occurring primarily through skin-to-skin genital contact and, less commonly, through vertical (mother-to-child) routes during delivery. Acquisition is near-universal among sexually active individuals, but the majority of infections resolve spontaneously through immune-mediated clearance within 1–2 years. Persistent infection with HR-HPV types, particularly HPV16 and HPV18, constitutes the necessary—though not sufficient—precondition for cervical carcinogenesis and a substantial proportion of other anogenital and oropharyngeal cancers 36.
2. Global Cancer Burden: Incidence and Mortality
According to IARC GLOBOCAN 2022 data, cervical cancer—the most directly HPV-attributable malignancy—accounted for 662,044 new cases and 348,709 deaths globally in 2022, yielding an age-standardized incidence rate (ASIR) of 14.12 per 100,000 and an age-standardized mortality rate (ASMR) of 7.08 per 100,000 24. The distribution of this burden is profoundly unequal: sub-Saharan Africa and South-East Asia carry disproportionate shares, with Africa recording the highest ASIR (31.8 per 100,000) and ASMR (21.4 per 100,000), while Europe reports the lowest (ASIR 10.1; ASMR 3.9 per 100,000) 24.
In the United States, CDC surveillance data (2018–2022) identify approximately 49,908 new HPV-associated cancer cases annually across anatomical sites where HPV is commonly detected. An estimated 39,300 (79%) of these cases are directly HPV-attributable. The site-specific breakdown is shown in Table 1 below 2.
Table 1. Annual U.S. HPV-Attributable Cancer Cases by Site and Sex (2018–2022)
| Cancer Site | HPV-Associated Cases/Year | HPV Attribution Rate | HPV-Attributable Cases |
|---|---|---|---|
| Cervix | 12,287 | 91% | 11,100 |
| Oropharynx (total) | 22,585 | 70% | 16,000 |
| — Male oropharyngeal | 18,776 | 72% | 13,600 |
| — Female oropharyngeal | 3,809 | 63% | 2,400 |
| Anus (total) | 8,348 | 91% | 7,600 |
| Vulva | 4,370 | 69% | 3,000 |
| Vagina | 889 | 75% | 700 |
| Penis | 1,429 | 63% | 900 |
A critical finding from U.S. data is the pronounced sex disparity in oropharyngeal cancer: men account for 18,776 of 22,585 HPV-associated oropharyngeal cases annually (male-to-female ratio approximately 4.9:1), reflecting a rising secular trend in HPV-positive oropharyngeal squamous cell carcinoma among middle-aged men in high-income settings 2.
3. HPV Infection Prevalence and Type Distribution
Pooled global estimates from systematic reviews and meta-analyses confirm that HPV16 is the most prevalent oncogenic genotype across anatomical sites. In women with abnormal cervical cytology, HPV16 predominates at approximately 32.98% of HPV-positive cases, followed by HPV31 (17.66%) and HPV51 (13.83%) in one population-based cohort study 13. Among women with invasive cervical cancer (ICC) in Eastern India (Odisha), HPV16 was detected in 87.28% of cases and HPV18 in 24.56%, with projected vaccine efficacy of 89.99% for the bivalent, 91.65% for the quadrivalent, and 92.16% for the nonavalent vaccine 18.
Regional variation in type distribution has important programmatic implications. In Suriname, a multi-ethnic country with an age-standardized cervical cancer incidence rate of 22.4 per 100,000, HPV16 accounts for only 25% of cervical cancers—markedly lower than the global norm—with HPV18 and HPV45 also prominent. The combined HPV16/18 fraction reaches only 43%, reducing projected vaccine efficacy to 28–30% and underscoring the need for locally tailored vaccination strategies in ethnically diverse populations 14. In Iran, HPV prevalence among healthy, noncancerous women was estimated at 9.4% (HPV16: 2.03%; HPV18: 1.7%; other genotypes: 5.3%), suggesting a substantial infection reservoir 11.
For older women (≥50 years) with abnormal cytology, a systematic review and meta-analysis of 113 studies found pooled any-HPV prevalence of 54.5% and high-risk HPV prevalence of 43.0%, with HPV16 present in 12.0% and HPV52 in 8.4% of cases. Higher HR-HPV prevalence was observed among women in Africa. These findings emphasize that age-inclusive screening strategies are essential for cervical cancer elimination 8.
Multisite HPV infection is also clinically significant. A meta-analysis of 41 observational studies found that cervical HPV-positive women had more than twice the odds of concurrent oral HPV infection (OR 2.22; 95% CI: 1.52–3.25), with oral HPV prevalence of 13% in cervical HPV-positive versus 4% in cervical HPV-negative women 20.
4. Etiology, Natural History, and Determinants of Progression
HPV is transmitted primarily through sexual contact; vertical transmission during delivery may lead to neonatal RRP, though this is rare. Following infection, most women clear the virus within 1–2 years through cell-mediated immunity. Persistent HR-HPV infection drives progressive cervical epithelial changes—from cervical intraepithelial neoplasia (CIN1) through CIN2/CIN3—to invasive cervical cancer, mediated mechanistically by viral E6 and E7 oncoproteins that inactivate tumor suppressors p53 and Rb, respectively, disrupting cell cycle control and apoptotic pathways 36.
A large population-based cohort study (n=7,778 HR-HPV-positive women) identified three host factors significantly associated with type-specific HR-HPV persistence: a history of genital warts (OR 1.35; 95% CI: 1.04–1.74), current oral contraceptive use (OR 1.35; 95% CI: 1.13–1.63), and systemic glucocorticoid use (OR 2.04; 95% CI: 1.16–3.56). Number of pregnancies, hormonal IUD use, and NSAID use were not significantly associated with persistence, suggesting that immune modulation—rather than hormonal effects per se—is the primary determinant of viral persistence and downstream cancer risk 34.
Immunosuppression due to HIV co-infection substantially amplifies HPV-related risk. A pooled analysis of 26 studies (n=11,177 women) found that cervical HPV16 prevalence in women with HIV (WWH) ranged from 18.3% in the 15–24 age group to 7.2% in women aged ≥55 years, compared to 7.4% to 1.7% in HIV-negative women. Crucially, anal HPV16 prevalence did not decline significantly with age in WWH (ranging 11.5%–13.9%; p-trend = 0.5412), in contrast to the significant age-related decline observed in HIV-negative women. Among WWH with HPV16-positive anal high-grade squamous intraepithelial lesions (HSIL+), 56% were concurrently positive for cervical high-risk HPV—underscoring the need for expanded anal cancer screening in this population 4.
5. Age-Specific Patterns and Genotyping for Risk Stratification
Age at vaccination is a critical determinant of efficacy. A systematic review of 21 studies (2007–2022) found vaccine effectiveness of 74–93% for girls vaccinated at ages 9–14 years, versus 12–90% for those vaccinated at ages 15–18 years; seventeen of twenty-one studies confirmed highest effectiveness in the youngest age group, providing robust evidence for the recommended vaccination window 15.
HPV genotyping combined with age stratification improves triage specificity. In a Northern Ireland study of 866 women with borderline or mild cytological abnormalities, HPV16/18 genotyping conferred a relative risk of ≥CIN2 of 2.23 overall. Importantly, HPV16 carried higher relative risk in women under 30 years (RR 1.74), while HPV18 risk was greatest in women aged ≥30 years (RR 3.03), supporting age-differentiated clinical management algorithms 9.
6. Temporal Trends and Vaccination Impact
Global HPV vaccination coverage for the primary target cohort (girls aged 9–14 years) reached 56.9% for first dose in 2024, recovering from a pandemic-associated decline (2018–2021 annual percentage change [APC]: −5.8%) to a robust upward trend (2021–2024 APC: +8.8%; p=0.022). Regional coverage in 2024 varied widely: South-East Asia 63.9%, Western Pacific 58.2%, Africa approximately 57.9%, Europe approximately 55.6%, Americas approximately 55.4%, and Eastern Mediterranean 19.5% 21. A broader systematic review incorporating 2023 WHO/UNICEF data found weighted average first-dose coverage of 61.6% (95% CI: 50.9%–71.8%) and full-dose coverage of 47.6% (95% CI: 39.7%–57.4%), with only 15 countries (11%) achieving the WHO 90% coverage target 3.
Evidence of vaccination impact is accumulating in early-adopting countries. In Scotland, bivalent vaccine effectiveness among fully vaccinated women was substantial: HPV16/18 positivity was 11% versus 29.4% in nonvaccinated women, with dose-dependent protection (3-dose OR 0.27; 95% CI: 0.19–0.37). Cross-protection against HPV31, 33, and 45 was also documented (3-dose OR 0.45; 95% CI: 0.29–0.68), and preliminary herd immunity was evident from declining HPV16/18 prevalence in unvaccinated women (OR 0.67; 95% CI: 0.47–0.96 in 2013 vs. 2009 baseline). No clinically relevant type replacement was identified 32.
Time-trend analysis across multiple countries now demonstrates declining cervical cancer incidence consistent with vaccination program impact 3. Population-level type distribution shifts are also emerging: a cohort study found lower prevalence of vaccine-preventable types (HPV16, HPV18, HPV31) in women aged ≤22 years compared to the 23–29 year cohort, with relatively higher prevalence of non-vaccine HR-HPV types in younger women, reinforcing the need for ongoing genotype surveillance 13.
The multisite efficacy of the HPV16/18 bivalent vaccine was assessed in the Costa Rica Vaccine Trial: among HPV-naïve women, multisite woman-level vaccine efficacy was 83.5% (95% CI: 72.1%–90.8%) at four-year follow-up, with partial but statistically significant protection (57.8%; 95% CI: 34.4%–73.4%) among women with prior HPV16/18 exposure 7.
7. Disease Burden Metrics: DALYs and Quality-of-Life Impact
Formal IHME Global Burden of Disease estimates for HPV-specific DALYs, YLLs, and YLDs were not available in the retrieved materials, representing a key data gap. Nonetheless, the scale of cervical cancer mortality—348,709 deaths globally in 2022, heavily concentrated in low- and middle-income countries (LMICs) where women are diagnosed at advanced stages—implies an enormous Years of Life Lost burden 24. In the Asia-Pacific region, cervical cancer incidence per 100,000 ranged from 15.4 to 252.0 across studies, while head and neck cancer incidence ranged from 0.2 to 55.5, and anal cancer from 0.2 to 13.7. HPV prevalence in penile cancer ranged from 36.0%–79.6%, and vaginal/vulvar cancer from 44.0%–82.0%. The substantial variability across Asia-Pacific studies reflects heterogeneous registry quality and the urgent need for improved data collection in data-scarce sub-regions 10.
Therapeutic vaccines for HPV-associated CIN2/3 show preliminary promise: a systematic review of 9 RCTs (800 participants) found statistically significant lesion regression to ≤CIN1 in the meta-analyzed subset (combined p=0.010, moderate-certainty evidence), though evidence for advanced cervical cancer remains very limited (2 RCTs, 123 participants; very low certainty) 12.
8. WHO Cervical Cancer Elimination Initiative and Prevention Framework
The WHO's 90–70–90 strategy aims by 2030 to achieve: (1) 90% of girls fully vaccinated with HPV vaccine by age 15; (2) 70% of women screened with a high-performance test by age 35 and again by 45; and (3) 90% of women with cervical disease receiving appropriate treatment. Mathematical modeling projects that achieving these targets in LMICs would avert more than 74 million new cervical cancer cases and over 62 million deaths by 2120, with a 97% reduction in cervical cancer incidence by 2120 133. Currently, global vaccination coverage remains substantially below the 90% target 321.
Screening paradigms are concurrently evolving. Primary HPV testing—superior in sensitivity to cytology—is increasingly replacing Pap-based programs, with triage of HPV-positive women using genotyping (HPV16/18 partial genotyping) combined with reflex liquid-based cytology or emerging biomarkers such as p16/Ki-67 dual staining and methylation testing 38. Australia, following national roll-out of high HPV vaccination coverage, transitioned to 5-yearly primary HPV screening with partial genotyping and reflex cytology in 2017, demonstrating the integration of vaccination and screening into a cost-effective cervical cancer prevention system 39. As vaccination coverage expands, mathematical projections indicate that within 25–30 years a tipping point may be reached where screening false-positives substantially outnumber true positives, necessitating further reductions in screening intensity 37.
9. Data Limitations and Uncertainties
Several important data gaps must be acknowledged. Global IHME GBD HPV-specific DALY estimates (YLLs, YLDs) were not extractable from retrieved materials. ECDC HPV surveillance reports for 2020–2025, ICO HPV Information Centre country-level prevalence data, genital warts and RRP incidence and QALY burden, and granular registry-based data for China, EU5 countries, and Latin America were not available in the retrieved source materials. Surveillance data quality varies substantially by region: cancer registries are incomplete or absent in many high-burden LMICs, oropharyngeal HPV surveillance remains limited globally, and testing assay heterogeneity complicates international prevalence comparisons 2110. The COVID-19 pandemic further disrupted screening programs and vaccination delivery between 2020 and 2021, contributing to the observed APC decline in vaccination coverage during that period 21. These limitations collectively underscore the need for strengthened global surveillance infrastructure, standardized assay platforms, and prospective cohort studies with cervical cancer endpoints in vaccinated populations 36.
10. Conclusion
HPV remains a leading infectious driver of cancer mortality worldwide, with cervical cancer alone causing approximately 349,000 deaths annually and oropharyngeal cancers rising sharply among men in high-income countries. Global vaccination coverage has recovered post-pandemic but remains well below the WHO 90% target, and only 15 countries have achieved that benchmark. Evidence from Scotland, Australia, and other high-coverage settings demonstrates clear vaccine-driven reductions in HPV16/18 prevalence and associated precancer, with cross-protection against related oncogenic types amplifying public health impact. Achieving the WHO 90–70–90 cervical cancer elimination targets, integrating HPV-based primary screening with risk-stratified triage, and expanding surveillance for non-cervical HPV-associated cancers constitute the central priorities for reducing HPV's global disease burden over the coming decade 133339.